Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Aug 31;109(3):895–905. doi: 10.3324/haematol.2023.283509

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2024 Ferrata Storti Foundation

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

PMC Copyright notice

Figure 2. — Survival outcomes in the intention-to-treat population. Progression-free survival (A) and overall survival (B) in the intention-to-treat population with melflufen, daratumumab, and dexamethasone (melflufen group) or daratumumab monotherapy (daratumumab group). ^aUnstratified hazard ratio (HR). ^bLog-rank P value. ^cOverall, 2 patients randomized to the daratumumab group crossed over to the melflufen group following documented disease progression. ^dPatients alive at the time of study termination were censored. CI: Confidence Interval; N: number; NR: not reached.